SPC285
Ravúlisúmab
Status:
VeittApplication date:
19.12.2019Application published:
15.1.2020Grant published:
15.7.2023
Max expiry date:
7.2.2024Medicine name:
UltomirisMedicine for children:
No
Timeline
Today
19.12.2019Application
15.1.2020Publication
15.7.2023Registration
7.2.2024Expires
Marketing license
IS authorization number:
EU/1/19/1371/001Date:
22.7.2019
Foreign authorization number:
EU/1/19/1371Date:
2.7.2019
Owner
Name:
Xencor, Inc.Address:
465 North Halstead Street, Suite 200, Pasadena, CA 91107 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2808343
Deadlines
TypeDeadline until
Type: Frestur til að fara yfir drög að vottorði
Deadline until: 12.07.2023